Ironwood Pharma (IRWD) Reports Q1 Lost Per Share of 24c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Ironwood Pharmaceuticals Provides First Quarter 2015 Investor Update
May 5, 2015 4:02 PM EDTLINZESS® (linaclotide) U.S. net sales of $95.5 million in first quarter 2015
Total LINZESS prescriptions increased approximately 90% in first quarter 2015 compared to first quarter 2014
Reported positive top-line data from IW-3718 Phase IIa study for refractory GERD
Advanced sGC platform with initiation of first candidate, IW-1973, into Phase I study
Established agreement with Exact Sciences to co-promote Cologuard®
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
